Cargando…
CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
BACKGROUND: Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuva...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204964/ https://www.ncbi.nlm.nih.gov/pubmed/22065993 http://dx.doi.org/10.1371/journal.pone.0026399 |
_version_ | 1782215265695563776 |
---|---|
author | Feng, Zhien Guo, Wei Zhang, Chenping Xu, Qin Zhang, Ping Sun, Jian Zhu, Hanguang Wang, Zhonghe Li, Jiang Wang, Lizhen Wang, Bingshun Ren, Guoxin Ji, Tong Tu, Wenyong Yang, Xihu Qiu, Weiliu Mao, Li Zhang, Zhiyuan Chen, Wantao |
author_facet | Feng, Zhien Guo, Wei Zhang, Chenping Xu, Qin Zhang, Ping Sun, Jian Zhu, Hanguang Wang, Zhonghe Li, Jiang Wang, Lizhen Wang, Bingshun Ren, Guoxin Ji, Tong Tu, Wenyong Yang, Xihu Qiu, Weiliu Mao, Li Zhang, Zhiyuan Chen, Wantao |
author_sort | Feng, Zhien |
collection | PubMed |
description | BACKGROUND: Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. METHODOLOGY AND FINDINGS: 224 patients with HNSCC were treated with either cisplatin-based chemotherapy followed by surgery and radiotherapy (neoadjuvant group, n = 100) or surgery and radiotherapy (non-neoadjuvant group, n = 124). CCND1 expression was assessed by immunohistochemistry. CCND1 levels were analyzed with chemotherapy response, disease-free survival (DFS) and overall survival (OS). There was no significant difference between the neoadjuvant group and non-neoadjuvant group in DFS and OS (p = 0.929 and p = 0.760) when patients treated with the indiscriminate administration of cisplatin-based chemotherapy. However, in the neoadjuvant group, patients whose tumors showed a low CCND1 expression more likely respond to chemotherapy (p<0.001) and had a significantly better OS and DFS than those whose tumors showed a high CCND1 expression (73% vs 8%, p<0.001; 63% vs 6%, p<0.001). Importantly, patients with a low CCND1 expression in neoadjuvant group received more survival benefits than those in non-neoadjuvant group (p = 0.016), however patients with a high CCND1 expression and treated with neoadjuvant chemotherapy had a significantly poor OS compared to those treated with surgery and radiotherapy (p = 0.032). A multivariate survival analysis also showed CCND1 expression was an independent predictive factor (p<0.001). CONCLUSIONS: This study suggests that some but not all patients with HNSCC may benefit from neoadjuvant chemotherapy with cisplatin-based regimen and CCND1 expression may serve as a predictive biomarker in selecting patients undergo less than two cycles of neoadjuvant chemotherapy. |
format | Online Article Text |
id | pubmed-3204964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32049642011-11-07 CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Feng, Zhien Guo, Wei Zhang, Chenping Xu, Qin Zhang, Ping Sun, Jian Zhu, Hanguang Wang, Zhonghe Li, Jiang Wang, Lizhen Wang, Bingshun Ren, Guoxin Ji, Tong Tu, Wenyong Yang, Xihu Qiu, Weiliu Mao, Li Zhang, Zhiyuan Chen, Wantao PLoS One Research Article BACKGROUND: Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. METHODOLOGY AND FINDINGS: 224 patients with HNSCC were treated with either cisplatin-based chemotherapy followed by surgery and radiotherapy (neoadjuvant group, n = 100) or surgery and radiotherapy (non-neoadjuvant group, n = 124). CCND1 expression was assessed by immunohistochemistry. CCND1 levels were analyzed with chemotherapy response, disease-free survival (DFS) and overall survival (OS). There was no significant difference between the neoadjuvant group and non-neoadjuvant group in DFS and OS (p = 0.929 and p = 0.760) when patients treated with the indiscriminate administration of cisplatin-based chemotherapy. However, in the neoadjuvant group, patients whose tumors showed a low CCND1 expression more likely respond to chemotherapy (p<0.001) and had a significantly better OS and DFS than those whose tumors showed a high CCND1 expression (73% vs 8%, p<0.001; 63% vs 6%, p<0.001). Importantly, patients with a low CCND1 expression in neoadjuvant group received more survival benefits than those in non-neoadjuvant group (p = 0.016), however patients with a high CCND1 expression and treated with neoadjuvant chemotherapy had a significantly poor OS compared to those treated with surgery and radiotherapy (p = 0.032). A multivariate survival analysis also showed CCND1 expression was an independent predictive factor (p<0.001). CONCLUSIONS: This study suggests that some but not all patients with HNSCC may benefit from neoadjuvant chemotherapy with cisplatin-based regimen and CCND1 expression may serve as a predictive biomarker in selecting patients undergo less than two cycles of neoadjuvant chemotherapy. Public Library of Science 2011-10-31 /pmc/articles/PMC3204964/ /pubmed/22065993 http://dx.doi.org/10.1371/journal.pone.0026399 Text en Feng et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Feng, Zhien Guo, Wei Zhang, Chenping Xu, Qin Zhang, Ping Sun, Jian Zhu, Hanguang Wang, Zhonghe Li, Jiang Wang, Lizhen Wang, Bingshun Ren, Guoxin Ji, Tong Tu, Wenyong Yang, Xihu Qiu, Weiliu Mao, Li Zhang, Zhiyuan Chen, Wantao CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma |
title | CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma |
title_full | CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma |
title_fullStr | CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma |
title_full_unstemmed | CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma |
title_short | CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma |
title_sort | ccnd1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204964/ https://www.ncbi.nlm.nih.gov/pubmed/22065993 http://dx.doi.org/10.1371/journal.pone.0026399 |
work_keys_str_mv | AT fengzhien ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT guowei ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT zhangchenping ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT xuqin ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT zhangping ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT sunjian ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT zhuhanguang ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT wangzhonghe ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT lijiang ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT wanglizhen ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT wangbingshun ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT renguoxin ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT jitong ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT tuwenyong ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT yangxihu ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT qiuweiliu ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT maoli ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT zhangzhiyuan ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma AT chenwantao ccnd1asapredictivebiomarkerofneoadjuvantchemotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinoma |